Cargando…
Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective
Charcot neuroarthropathy (CN) is a chronic, destructive, and painless damage of the skeletal system that affects the life quality of patients. CN, with an unclear mechanism, is characterized with invasive destruction of bones and a serious abnormality of bone metabolism. Unfortunately, development o...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130761/ https://www.ncbi.nlm.nih.gov/pubmed/37124200 http://dx.doi.org/10.3389/fphar.2023.1160278 |
_version_ | 1785031027722289152 |
---|---|
author | Liu, Liang Wang, Qiong Zhang, Yan Liang, Jingqi Liu, Peilong Zhao, Hongmou |
author_facet | Liu, Liang Wang, Qiong Zhang, Yan Liang, Jingqi Liu, Peilong Zhao, Hongmou |
author_sort | Liu, Liang |
collection | PubMed |
description | Charcot neuroarthropathy (CN) is a chronic, destructive, and painless damage of the skeletal system that affects the life quality of patients. CN, with an unclear mechanism, is characterized with invasive destruction of bones and a serious abnormality of bone metabolism. Unfortunately, development of an effective prevention and treatment strategy for CN is still a great challenge. Of note, recent studies providing an insight into the molecular mechanisms of bone metabolism and homeostasis have propelled development of novel CN therapeutic strategies. Therefore, this review aims to shed light on the pathogenesis, diagnosis, and treatment of CN. In particular, we highlight the eminent role of the osteoprotegerin (OPG)-receptor activator of nuclear factor-κB (RANK)-RANK ligand (RANKL) system in the development of CN. Furthermore, we summarize and discuss the diagnostic biomarkers of CN as well as the potential pharmacological mechanisms of current treatment regimens from the perspective of bone metabolism. We believe that this review will enhance the current state of knowledge on the diagnosis, prevention, and therapeutic efficacy of CN. |
format | Online Article Text |
id | pubmed-10130761 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101307612023-04-27 Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective Liu, Liang Wang, Qiong Zhang, Yan Liang, Jingqi Liu, Peilong Zhao, Hongmou Front Pharmacol Pharmacology Charcot neuroarthropathy (CN) is a chronic, destructive, and painless damage of the skeletal system that affects the life quality of patients. CN, with an unclear mechanism, is characterized with invasive destruction of bones and a serious abnormality of bone metabolism. Unfortunately, development of an effective prevention and treatment strategy for CN is still a great challenge. Of note, recent studies providing an insight into the molecular mechanisms of bone metabolism and homeostasis have propelled development of novel CN therapeutic strategies. Therefore, this review aims to shed light on the pathogenesis, diagnosis, and treatment of CN. In particular, we highlight the eminent role of the osteoprotegerin (OPG)-receptor activator of nuclear factor-κB (RANK)-RANK ligand (RANKL) system in the development of CN. Furthermore, we summarize and discuss the diagnostic biomarkers of CN as well as the potential pharmacological mechanisms of current treatment regimens from the perspective of bone metabolism. We believe that this review will enhance the current state of knowledge on the diagnosis, prevention, and therapeutic efficacy of CN. Frontiers Media S.A. 2023-04-12 /pmc/articles/PMC10130761/ /pubmed/37124200 http://dx.doi.org/10.3389/fphar.2023.1160278 Text en Copyright © 2023 Liu, Wang, Zhang, Liang, Liu and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Liu, Liang Wang, Qiong Zhang, Yan Liang, Jingqi Liu, Peilong Zhao, Hongmou Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective |
title | Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective |
title_full | Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective |
title_fullStr | Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective |
title_full_unstemmed | Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective |
title_short | Therapeutics of Charcot neuroarthropathy and pharmacological mechanisms: A bone metabolism perspective |
title_sort | therapeutics of charcot neuroarthropathy and pharmacological mechanisms: a bone metabolism perspective |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130761/ https://www.ncbi.nlm.nih.gov/pubmed/37124200 http://dx.doi.org/10.3389/fphar.2023.1160278 |
work_keys_str_mv | AT liuliang therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective AT wangqiong therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective AT zhangyan therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective AT liangjingqi therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective AT liupeilong therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective AT zhaohongmou therapeuticsofcharcotneuroarthropathyandpharmacologicalmechanismsabonemetabolismperspective |